Darzalex Triple Combo Approved in England for Difficult-to-treat Multiple Myeloma
A triple combination of Darzalex (daratumumab), Velcade…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreA triple combination of Darzalex (daratumumab), Velcade…
Janssen has is seeking approval from the U.S. Food and…
NantKwest and ProMab Biotechnologies are collaborating to develop…
A combination of Kyprolis (carfilzomib) and…
CT053, one of CARsgen Therapeutics‘ lead CAR T-cell…
An under-the-skin injection of daratumumab is as effective as…